Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kronos Bio, Inc. (KRON) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kronos Bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1741830.
Total stock buying since 2020: $38,864,694.
Total stock sales since 2020: $7,056,191.
Total stock option exercises since 2020: $90,144.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 3,620,640 | $3,852,472 | 61,560 | $68,787 | 0 | $0 |
| 2023 | 1,731,056 | $1,471,209 | 79,938 | $127,392 | 0 | $0 |
| 2022 | 597,129 | $2,251,225 | 27,795 | $50,169 | 0 | $0 |
| 2021 | 17,106 | $221,368 | 299,162 | $6,809,843 | 27,567 | $90,144 |
| 2020 | 1,635,180 | $31,068,420 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-06 | 3,620,640 | $3,852,472 | 0 | $0 | 0 | $0 |
| 2024-02 | 0 | $0 | 31,509 | $33,208 | 0 | $0 |
| 2024-01 | 0 | $0 | 30,051 | $35,579 | 0 | $0 |
| 2023-12 | 0 | $0 | 27,399 | $35,754 | 0 | $0 |
| 2023-11 | 1,731,056 | $1,471,209 | 0 | $0 | 0 | $0 |
| 2023-07 | 0 | $0 | 27,069 | $47,423 | 0 | $0 |
| 2023-02 | 0 | $0 | 25,470 | $44,215 | 0 | $0 |
| 2022-12 | 0 | $0 | 27,795 | $50,169 | 0 | $0 |
| 2022-05 | 597,129 | $2,251,225 | 0 | $0 | 0 | $0 |
| 2021-12 | 15,506 | $186,797 | 27,788 | $349,922 | 0 | $0 |
| 2021-10 | 0 | $0 | 9,189 | $191,195 | 9,189 | $30,048 |
| 2021-09 | 0 | $0 | 9,189 | $201,303 | 9,189 | $30,048 |
| 2021-08 | 1,000 | $19,565 | 9,189 | $189,164 | 9,189 | $30,048 |
| 2021-05 | 600 | $15,006 | 0 | $0 | 0 | $0 |
| 2021-04 | 0 | $0 | 243,807 | $5,878,259 | 0 | $0 |
| 2020-10 | 1,635,180 | $31,068,420 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-06-28 | Bischofberger Norbert W (PRESIDENT & CEO) | Buy | 204,670 | 1.25 | 255,018 |
| 2024-06-27 | Bischofberger Norbert W (PRESIDENT & CEO) | Buy | 410,848 | 1.17 | 479,048 |
| 2024-06-12 | Bischofberger Norbert W (PRESIDENT & CEO) | Buy | 881,913 | 1.24 | 1,096,217 |
| 2024-06-11 | Bischofberger Norbert W (PRESIDENT & CEO) | Buy | 744,308 | 1.09 | 814,272 |
| 2024-06-10 | Bischofberger Norbert W (PRESIDENT & CEO) | Buy | 1,378,901 | .88 | 1,207,917 |
| 2024-02-21 | Lin Charles Y (SR VP, RESEARCH & DEVELOPMENT) | Sale | 12,036 | 1.05 | 12,685 |
| 2024-02-21 | Frisbee Allison (SR VP, CORP OPERATIONS & LEGAL) | Sale | 12,105 | 1.05 | 12,758 |
| 2024-02-21 | Olek Elizabeth A (SR VP, CLINICAL SCIENCE) | Sale | 7,368 | 1.05 | 7,765 |
| 2024-01-04 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 7,366 | 1.18 | 8,721 |
| 2024-01-04 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 12,009 | 1.18 | 14,218 |
| 2024-01-04 | Kosacz Barbara (COO & General Counsel) | Sale | 10,676 | 1.18 | 12,640 |
| 2023-12-12 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 10,032 | 1.30 | 13,091 |
| 2023-12-12 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 17,367 | 1.30 | 22,663 |
| 2023-11-17 | Bischofberger Norbert W (President & CEO) | Buy | 97,935 | 1.08 | 106,161 |
| 2023-11-16 | Bischofberger Norbert W (President & CEO) | Buy | 262,433 | 1.00 | 261,645 |
| 2023-11-15 | Bischofberger Norbert W (President & CEO) | Buy | 1,370,688 | .81 | 1,103,403 |
| 2023-07-06 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 6,634 | 1.75 | 11,622 |
| 2023-07-06 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 10,818 | 1.75 | 18,953 |
| 2023-07-06 | Al-wakeel Yasir B. (Chief Financial Officer) | Sale | 9,617 | 1.75 | 16,848 |
| 2023-02-24 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 6,291 | 1.74 | 10,921 |
| 2023-02-24 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 10,153 | 1.74 | 17,625 |
| 2023-02-24 | Al-wakeel Yasir B. (Chief Financial Officer) | Sale | 9,026 | 1.74 | 15,669 |
| 2022-12-12 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 9,138 | 1.80 | 16,494 |
| 2022-12-12 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 18,657 | 1.80 | 33,675 |
| 2022-05-19 | Bischofberger Norbert W (President & CEO) | Buy | 300,000 | 3.78 | 1,134,600 |
| 2022-05-18 | Bischofberger Norbert W (President & CEO) | Buy | 206,198 | 3.73 | 768,087 |
| 2022-05-17 | Bischofberger Norbert W (President & CEO) | Buy | 90,931 | 3.83 | 348,538 |
| 2021-12-13 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 11,386 | 12.59 | 143,372 |
| 2021-12-13 | Dimartino Jorge (Chief Medical Officer & VP) | Sale | 16,402 | 12.59 | 206,550 |
| 2021-12-06 | Bischofberger Norbert W (President & CEO) | Buy | 14,356 | 12.09 | 173,492 |
| 2021-12-01 | De Backer Marianne (Director) | Buy | 1,150 | 11.57 | 13,305 |
| 2021-10-04 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 9,189 | 20.81 | 191,195 |
| 2021-10-04 | Dinsmore Christopher (Chief Scientific Officer) | Option Ex | 9,189 | 3.27 | 30,048 |
| 2021-09-07 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 9,189 | 21.91 | 201,303 |
| 2021-09-07 | Dinsmore Christopher (Chief Scientific Officer) | Option Ex | 9,189 | 3.27 | 30,048 |
| 2021-08-20 | De Backer Marianne (Director) | Buy | 1,000 | 19.57 | 19,565 |
| 2021-08-02 | Dinsmore Christopher (Chief Scientific Officer) | Sale | 9,189 | 20.59 | 189,164 |
| 2021-08-02 | Dinsmore Christopher (Chief Scientific Officer) | Option Ex | 9,189 | 3.27 | 30,048 |
| 2021-05-28 | De Backer Marianne (Director) | Buy | 600 | 25.01 | 15,006 |
| 2021-04-20 | Loven Jakob (Director) | Sale | 21,551 | 20.36 | 438,886 |
| 2021-04-19 | Loven Jakob (Director) | Sale | 14,004 | 20.82 | 291,493 |
| 2021-04-16 | Loven Jakob (Director) | Sale | 33,162 | 21.20 | 703,034 |
| 2021-04-15 | Loven Jakob (Director) | Sale | 24,818 | 21.78 | 540,536 |
| 2021-04-14 | Loven Jakob (Director) | Sale | 32,636 | 22.74 | 742,142 |
| 2021-04-13 | Loven Jakob (Director) | Sale | 17,020 | 24.31 | 413,756 |
| 2021-04-12 | Loven Jakob (Director) | Sale | 15,828 | 26.74 | 423,240 |
| 2021-04-09 | Loven Jakob (Director) | Sale | 21,660 | 27.20 | 589,152 |
| 2021-04-08 | Loven Jakob (Director) | Sale | 63,128 | 27.50 | 1,736,020 |
| 2020-10-14 | Dinsmore Christopher (Chief Scientific Officer) | Buy | 5,250 | 19.00 | 99,750 |
| 2020-10-14 | Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust (10% Owner) | Buy | 95,500 | 19.00 | 1,814,500 |
| 2020-10-14 | Ridloff Elena (Director) | Buy | 2,630 | 19.00 | 49,970 |
| 2020-10-14 | Kosacz Barbara (COO & General Counsel) | Buy | 5,250 | 19.00 | 99,750 |
| 2020-10-14 | Al-wakeel Yasir B. (Chief Financial Officer) | Buy | 5,250 | 19.00 | 99,750 |
| 2020-10-14 | Stampacchia Otello (Director) | Buy | 900,000 | 19.00 | 17,100,000 |
| 2020-10-14 | Martin John C (Director) | Buy | 75,800 | 19.00 | 1,440,200 |
| 2020-10-14 | Bischofberger Norbert W (President & CEO) | Buy | 95,500 | 19.00 | 1,814,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of KRON listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kronos Bio, Inc. (symbol KRON, CIK number 1741830) see the Securities and Exchange Commission (SEC) website.